log  
logo
A Journal of Postdoctoral Research.
 
     Login   |   Register   
    ISSN : 2328-9791
left right
 
 
Hall of Fame
EDITORIAL BOARD
btm
 
top
  Dr. STEFANIE MARQUEZ  
 
Address 1 :
Address 2 :
Title : Dr.
First Name : STEFANIE
Last Name : MARQUEZ
University/Institution : University of Florida
Email ID : stefanie.marquez@ufl.edu
City : Gainesville
Country : United States
State : Florida
Zipcode : 32606
Department : Medicine; Hematology/Oncology
Company Name :
Area of Research
Cancer
Area of Expertise
SWI/SNF and cancer; neurodegenerative disease
Brief Description of Research Interest :
My lab studies the SWI/SNF chromatin remodeling complex and its relationship to cancer. We focus our efforts particularly on the ATPase subunits, BRM and BRG1, which are frequently lost in many solid tumors. I am currently trying to show that when BRG1 is lost in a variety of tumor types, it is not mutated in the majority of cases, but rather, it is epigenetically silenced, akin to its homologue BRM. We have also begun a similar study with regards to the loss of PBRM1 (BAF180) in human renal cell carcinoma.

In addition, we are conducting a validation study for the presence of two polymorphic inserts in the BRM promoter to see if the results match our initial pilot study that was published several years ago for lung cancer. In addition to lung and head and neck (both published), we are expanding our study to include colorectal, breast, prostate, renal cell and esophageal cancers. The presence of the two inserts confers a greater risk for lung and head and neck cancers, as the sequence of the inserts binds several key transcription factors which regulate BRM expression.

Lastly, we have a mouse model for lung cancer, whereby tumors are induced by a carcinogen in BRM null, BRG1 conditional knockout and double BRG1/BRM knockout mice. We have observed significantly more aggressive tumors (and even distant metastases) in the BRG1 knockout and double knockout mice compared to the other groups. My lab is also interested in translational therapies for cancer.
Representative Publications :

  ChowTW, Varpetian A, Moss T, Vinters HV, Marquez S, Miller C. Alzheimer'sdisease neuropathologic changes in semantic dementia. Neurocase. 2010 Feb; 16(1):15-22. Epub 2009 Oct 28.


·        Reisman DN, Marquez S. Biomarkers can Promote Risk Stratificationfor Lung Cancer Detection. Journal of Clinical and Experimental Oncology July2012.

 Kahali B, Gramling S, Marquez S, Reisman DN. Identifying Targetsfor Restoring and 

Reactivating BRM.Oncogene. March 2013. 

·        Wang JR,Gramling SJ, Goldstein DP, Cheng D, Chen D, Azad AK, Tse A, Hon H, Chen Z,     

 Mirshams M, Simpson C, Huang SH, Marquez S, O'Sullivan B, Liu FF,Roberts H, Xu W,  


BrownDH, Gilbert RW, Gullane PJ, Irish JC, Reisman DN, Liu G.  Association of two BRM promoter   

polymorphisms with head and necksquamous cell carcinoma risk. Carcinogenesis,February 2013


Marquez S, Kahali B,Thompson K, Gramling S, Liang S, Lu L, Aponick A, Reisman DN. FlavonoidsReactive BRM: An Important co-factor for the anti-cancer Gene Effects ofFlavonoids. Molecular Cancer Therapeutics. Submitted, January 2014

·        Thompson K; MarquezS, Reisman DN. A synthetic lethality-based strategy to treat cancers harboringa genetic deficiency in the chromatin remodeling factor BRG1-Letter. CancerResearch 2014. Accepted pending response/rebuttal from other authors.


Marquez S, Thompson K, Gramling S, Kahali B, Lu L, Reisman D. BRG1 Loss in HumanTumors. (In preparation)


Resume : Download
 
     
btm
 
 
top
 
 
 
 
 
btm

 
footer
 
 
home phone mail info@postdocjournal.com
 
twitter facebook social icon Social link You Tube sky
Click Here